Lyra Therapeutics Capex To Revenue Over Time
| LYRA Stock | USD 0.18 0.01 5.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lyra Therapeutics Performance and Lyra Therapeutics Correlation. Lyra |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.023 | Quarterly Revenue Growth (0.64) | Return On Assets (0.42) | Return On Equity (1.86) |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capex To Revenue Analysis
Compare Lyra Therapeutics and related stocks such as CytomX Therapeutics, Assembly Biosciences, and Achilles Therapeutics PLC Capex To Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTMX | 0.8243 | 0.8243 | 0.8243 | 0.8243 | 0.3276 | 0.2067 | 0.1447 | 0.0218 | 0.0637 | 0.0608 | 0.023 | 0.0231 | 0.0327 | 0.0083 | 0.0079 |
| ASMB | 0.0959 | 0.0959 | 0.0959 | 0.0959 | 0.0959 | 0.0959 | 0.0959 | 0.0959 | 0.023 | 0.0974 | 0.0281 | 0.495 | 0.0356 | 0.032 | 0.0304 |
| ACHL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TIL | 368 | 368 | 368 | 368 | 368 | 368 | 368 | 368 | 368 | 368 | 368 | 368 | 368 | 331 | 295 |
| NXTC | 0.5311 | 0.5311 | 0.5311 | 0.5311 | 0.5311 | 0.5311 | 0.5311 | 0.5311 | 0.5311 | 0.5311 | 0.3187 | 0.3187 | 0.3187 | 0.37 | 0.46 |
| NUVB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CGEM | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.0311 | 0.028 | 0.0249 |
| BOLT | 2.3628 | 2.3628 | 2.3628 | 2.3628 | 2.3628 | 2.3628 | 2.3628 | 2.3628 | 2.3628 | 2.3628 | 14.1212 | 1.8556 | 0.3409 | 0.0262 | 0.0248 |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| AUTL | 8.0974 | 8.0974 | 8.0974 | 8.0974 | 8.0974 | 1.5305 | 1.6988 | 8.3909 | 6.4195 | 6.4195 | 60.6653 | 3.8013 | 1.7502 | 6.47 | 8.78 |
Lyra Therapeutics and related stocks such as CytomX Therapeutics, Assembly Biosciences, and Achilles Therapeutics PLC Capex To Revenue description
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.My Equities
My Current Equities and Potential Positions
| Lyra Therapeutics | LYRA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.18
Check out Lyra Therapeutics Performance and Lyra Therapeutics Correlation. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Lyra Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.